CLINICAL TRIAL article
Front. Neurol.
Sec. Experimental Therapeutics
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1566476
Low intensity gamma-frequency TMS safely modulates gamma oscillations in probable mild Alzheimer's dementia: a randomized 2x2 crossover pilot study
Provisionally accepted- 1Department of Geriatric Medicine & Neurology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
- 2Faculty of Medicine, National Autonomous University of Mexico, Mexico City, México, Mexico
- 3Actipulse Neuroscience, Inc., Cambridge, Massachussetts, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: AD is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss. While traditional treatments targeting beta-amyloid accumulation have shown limited success, there is a pressing need for novel therapeutic approaches. Recent studies have highlighted the role of disrupted gamma oscillations in AD pathology, leading to the exploration of gamma neuromodulation as a potential therapeutic strategy to modify disease progression in individuals with AD dementia. This pilot clinical trial aimed to investigate the electrophysiological effects of low intensity gamma transcranial magnetic stimulation (gTMS) on gamma oscillations in patients with a diagnosis of probable mild AD dementia. Methods: Employing a randomized, double-blind, sham-controlled, 2x2 crossover design, participants underwent a single session of both real low intensity gTMS and sham stimulation. EEG recordings and cognitive assessments were conducted before and after stimulation to assess changes in brain activity and their impact on episodic memory. Results: We observed statistically significant changes in EEG activity (n=14), indicating transient modulation of gamma oscillations immediately after low intensity gTMS. There was no significant improvement in cognition compared to baseline scores, but we evidenced a positive correlation between electrophysiological changes and cognitive outcome. Importantly, the intervention was well-tolerated, with no significant adverse effects reported. Discussion: Low intensity gTMS has shown the capability to induce significant changes in brain activity, particularly in gamma oscillations. These findings suggest that low intensity gTMS holds promise as a safe and non-invasive therapeutic approach, challenging the conventional belief that high intensity magnetic pulses are necessary for effective brain modulation. To corroborate these initial findings, further research with extended intervention durations and larger, well-defined cohorts of patients with mild AD dementia is essential. This will validate the potential benefits of low intensity gTMS on cognitive performance in this population.
Keywords: Neuromodulation, Alzheimer's disease, Mild Cognitive Impairment, gamma oscillations, Transcranial Magnetic Stimulation, gamma TMS
Received: 24 Jan 2025; Accepted: 16 Apr 2025.
Copyright: © 2025 Mimenza, Aguilar-Navarro, Abarca-Jiménez, Vazquez-Villaseñor, Luna-Umanzor, Dorard and Villafuerte. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Gabriel Villafuerte, Actipulse Neuroscience, Inc., Cambridge, Massachussetts, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.